Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,11
KB-1,02
PKN64,9464,96-1,25
Msft428,19428,24-0,45
Nokia3,5313,5935-0,29
IBM168,76168,79-1,22
Mercedes-Benz Group AG66,4866,50,14
PFE28,1828,19-2,41
28.05.2024 20:45:42
Indexy online
AD Index online
select
AD Index online
 

  • 27.05.2024
Bankinter (BKT.MC, Madrid CATS)
Závěr k 27.5.2024 Změna (%) Změna (EUR) Objem obchodů (EUR)
7,92 -0,18 -0,01 -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 28.05.2024
Popis společnosti
Obecné informace
Název společnostiBankinter SA
TickerBKT
Kmenové akcie:Ordinary Shares
RICBKT.MC
ISINES0113679I37
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky31.03.2024
Počet zaměstnanců k 31.03.2024 6 562
Akcie v oběhu k 31.03.2024 898 589 000
MěnaEUR
Kontaktní informace
UlicePaseo de la Castellana, 29
MěstoMADRID
PSČ28046
ZeměSpain
Kontatní osobaLaurie Shepard Goodroe
Funkce kontaktní osobyIR Contact Officer
Telefon34 913 397 500
Fax34913397522
Kontatní telefon34 913 397 500

Business Summary: Bankinter SA is a Spain-based financial institution (the Bank) primarily engaged in the banking sector. The Bank's activities are divided into four business segments: Commercial banking, which offers current accounts, fixed-term deposits, investment management and advisory, as well as mortgage loans, among others, to individual customers; Corporate banking, which provides financial services to small and medium-sized companies, corporations and government bodies; Consumer finance, which focuses on personal loans and credit card services through Bankinter Consumer Finance EFC, and Other, which includes online savings accounts, among others. The Company operates through numerous subsidiaries, such as Bankinter Gestion de Activos SGIIC, Hispamarket SA, Bankinter Capital Riesgo SGECR SA and Bankinter Sociedad de Financiacion SAU.
Financial Summary: BRIEF: For the three months ended 31 March 2024, Bankinter SA interest income increased 51% to EUR1.08B. Net interest income after loan loss provision increased 11% to EUR497.1M. Net income increased 9% to EUR200.8M. Net interest income after loan loss provision reflects increase in interest earning assets and decrease in interest bearing liabilities.
Odvětvová klasifikace
TRBC2009Banks
TRBC2012Banks (NEC)
RBSS2004Banks
MGINDUSTRYMoney Center Banks
MGSECTORFinancial
NAICSCommercial Banking
NAICSInvestment Banking and Securities Intermediation
NAICSPortfolio Management and Investment Advice
NAICSInternational, Secondary Market, and All Other Nondepository Credit Intermediation
NAICSInsurance Agencies and Brokerages
NAICS2007Commercial Banking
NAICS2007Investment Banking and Securities Dealing
NAICS2007Portfolio Management
NAICS2007All Oth Nondepository Credit Intermediation
NAICS2007Securities Brokerage
NAICS2007Insurance Agencies and Brokerages
NAICS2007Investment Advice
NAICS2007Direct Life Insurance Carriers
NAICS2007Direct Health & Medical Insurance Carriers
NAICS2007Direct Property & Casualty Insurance Carriers
NAICS1997Commercial Banking
NAICS1997Investment Banking and Securities Dealing
NAICS1997Portfolio Management
NAICS1997All Other Non-Depository Credit Intermediation
NAICS1997Securities Brokerage
NAICS1997Insurance Agencies and Brokerages
NAICS1997Investment Advice
NAICS1997Direct Life Insurance Carriers
NAICS1997Direct Health and Medical Insurance Carriers
NAICS1997Direct Property and Casualty Insurance Carriers
SICCommercial Banks, Nec
SICSecurity Brokers And Dealers
SICInvestment Advice
SICMisc Business Credit Institutions
SICInsurance Agents/brokers/service



  • Poslední aktualizace: 28.05.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, Executive DirectorPascal Soriot6401.10.201201.10.2012
Chief Financial Officer, Executive DirectorAradhana Sarin-01.08.202101.08.2021
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZenecaMarc Dunoyer7001.08.202101.01.2013
Chief Human Resource Officer, Chief Compliance Officer, General CounselJeffrey Pott-01.01.2009
Executive Vice President - BioPharmaceuticals R&DSharon Barr-
Executive Vice President - Global Operations, Information Technology and Chief Sustainability OfficerPam Cheng-
Executive Vice President - BioPharmaceuticals Business UnitRuud Dobber59
Executive Vice President - Oncology Business UnitDavid Fredrickson-
Executive Vice President - Oncology and Research and DevelopmentSusan Galbraith-
Executive Vice President - Vaccines and Immune TherapiesIskra Reic-